Kuros Biosciences AG (SWX:KURN)
Switzerland · Delayed Price · Currency is CHF 21.16
-0.36 (-1.67%)
Aug 24, 2026, 5:31 PM CET
Kuros Biosciences AG Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 174.93 | 146.06 | 85.16 | 39.86 | 19.45 | 15.15 | |
Revenue Growth | 42.45% | 71.51% | 113.65% | 104.92% | 28.35% | 231.96% |
Cost of Revenue | 23.85 | 18.61 | 9.49 | 6.05 | 3.91 | 4.11 |
Gross Profit | 151.08 | 127.45 | 75.67 | 33.81 | 15.54 | 11.04 |
Selling, General & Admin | 127.05 | 107.95 | 67.81 | 37.73 | 20.96 | 15.41 |
Research & Development | 13.53 | 10.67 | 7.87 | 2.41 | 5.62 | 5.47 |
Other Operating Expenses | -0.12 | -0.13 | -0.13 | -0.29 | -0.39 | -0.23 |
Operating Expenses | 140.46 | 118.5 | 75.55 | 39.85 | 26.19 | 20.66 |
Operating Income | 10.62 | 8.95 | 0.12 | -6.04 | -10.65 | -9.62 |
Interest Expense | - | -0.37 | -0.17 | -0.22 | - | -1.52 |
Interest & Investment Income | 3.8 | 0.1 | 0.18 | - | - | 0.65 |
Currency Exchange Gain (Loss) | -3.56 | -3.56 | 1.32 | -2.73 | -0.86 | - |
Other Non Operating Income (Expenses) | -0.11 | -0.11 | 0.52 | 2.77 | -1.89 | - |
EBT Excluding Unusual Items | 10.76 | 5.02 | 1.98 | -6.22 | -13.4 | -10.48 |
Impairment of Goodwill | - | - | -5.75 | -5.19 | -3.89 | - |
Asset Writedown | - | - | - | -0.2 | - | - |
Pretax Income | 10.76 | 5.02 | -3.77 | -11.61 | -17.29 | -10.48 |
Income Tax Expense | 1.85 | 2.55 | 0.42 | 0.45 | -1.51 | -2.21 |
Earnings From Continuing Operations | 8.9 | 2.46 | -4.19 | -12.06 | -15.78 | -8.27 |
Earnings From Discontinued Operations | 0.07 | 0.09 | -0.65 | -4.24 | - | - |
Net Income | 8.97 | 2.55 | -4.84 | -16.3 | -15.78 | -8.27 |
Net Income to Common | 8.97 | 2.55 | -4.84 | -16.3 | -15.78 | -8.27 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 38 | 38 | 37 | 37 | 34 | 33 |
Shares Outstanding (Diluted) | 41 | 41 | 37 | 37 | 34 | 33 |
Shares Change | -9.33% | 11.26% | 1.69% | 7.91% | 3.37% | 34.86% |
EPS (Basic) | 0.23 | 0.07 | -0.13 | -0.45 | -0.47 | -0.25 |
EPS (Diluted) | 0.22 | 0.06 | -0.13 | -0.45 | -0.47 | -0.25 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -2.89 | 2.31 | -10.88 | -8.37 | -6.32 |
Free Cash Flow Per Share | - | -0.07 | 0.06 | -0.30 | -0.25 | -0.19 |
Gross Margin | 86.37% | 87.26% | 88.85% | 84.83% | 79.89% | 72.86% |
Operating Margin | 6.07% | 6.13% | 0.14% | -15.15% | -54.74% | -63.46% |
Profit Margin | 5.13% | 1.75% | -5.68% | -40.90% | -81.15% | -54.59% |
Free Cash Flow Margin | - | -1.98% | 2.71% | -27.29% | -43.05% | -41.72% |
EBITDA | 13.38 | 11.52 | 2.32 | -3.55 | -8.11 | -6.96 |
EBITDA Margin | 7.65% | 7.89% | 2.72% | -8.91% | -41.70% | -45.90% |
D&A For EBITDA | 2.76 | 2.57 | 2.2 | 2.49 | 2.54 | 2.66 |
EBIT | 10.62 | 8.95 | 0.12 | -6.04 | -10.65 | -9.62 |
EBIT Margin | 6.07% | 6.13% | 0.14% | -15.15% | -54.74% | -63.46% |
Effective Tax Rate | 17.23% | 50.91% | - | - | - | - |
Revenue as Reported | 146.06 | 146.06 | 85.16 | 39.86 | 19.45 | 15.15 |